Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab and Dabrafenib in Stage III/IV Melanoma
NCT02200562Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ipilimumab and dabrafenib + trametinib in melanoma, sponsored by University of Utah. Primary endpoint: Safety of ipilimumab and dabrafenib in combination at 24 weeks. Started Dec 2014; status: terminated.
02
Drugs
ipilimumabdabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02200562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02200562.